JNJ-38877605
JNJ-38877605 Basic information
- Product Name:
- JNJ-38877605
- Synonyms:
-
- JNJ-38877618
- JNJ-38877618 (OMO1
- OMO-1)
- 6-(difluoro(6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinoline
- Quinoline, 6-[difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]-
- 6-[Difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline
- JNJ-38877618,Inhibitor,c-Met/HGFR,JNJ 38877618,JNJ38877618,inhibit
- Venadaparib Impurity 21
- CAS:
- 943540-74-7
- MF:
- C20H12F2N6
- MW:
- 374.35
- Mol File:
- 943540-74-7.mol
More
Less
JNJ-38877605 Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- DMSO : 5 mg/mL (13.36 mM)
More
Less
JNJ-38877605 Usage And Synthesis
Biological Activity
JNJ-38877618 (OMO-1) is a potent, highly selective, and orally bioavailable Met (c-Met) kinase inhibitor with a Kd of 1.4 nM. Its IC50 values for wild-type Met (c-Met) and mutant Met (c-Met) (M1268T) were 2 nM and 3 nM, respectively.
in vivo
In vivo, JNJ-38877618(OMO-1) completely inhibited tumor growth in 3 tumor models: SNU5 MET amp gastric cancer model, U87-MG HGF autocrine glioblastoma model, and exon 14 skipping deletion mutation Hs746T gastric cancer model of MET gene. Administration of OMO-1 in combination with other drugs is well tolerated and can improve and enhance the effect of EGFR-targeted therapy. Although single-agent OMO-1 has no effect on NSCLC HCC827 EGFR, its combination with erlotinib can delay tumor recurrence.